KEGG   DISEASE: Macular edemaHelp
Entry
H01651                      Disease                                

Name
Macular edema
Description
Macular edema is a common feature of many diseases of the retina, such as intraocular inflammation (uveitis), central or branch retinal vein occlusion, diabetic retinopathy and following cataract extraction. It is characterized by a retinal thickening in the macular area due to the breakdown of the blood-retinal barrier. Extracellular fluid accumulates in the intraretinal area or collects in the subretinal space. In more severe cases, it occurs as cystoid edema with the typical petaloid appearance, and is the leading cause of visual loss. New treatments for macular edema have emerged over the past decade, the most recent and efficacious of which have involved blockage of vascular endothelial growth factor (VEGF) by frequent intravitreal injection of pharmacologic agents.
Category
Nervous system disease
Brite
Human diseases [BR:br08402]
 Nervous system diseases
  Eye disease
   H01651  Macular edema
Human diseases in ICD-11 classification [BR:br08403]
 09 Diseases of the visual system
  Disorders of the eyeball posterior segment
   Disorders of the retina
    9B75  Macular Disorders
     H01651  Macular edema
BRITE hierarchy
Drug
Dexamethasone [DR:D00292]
Aflibercept [DR:D09574]
Ranibizumab [DR:D05697]
Other DBs
ICD-11: 9B75.Y
ICD-10: H35.8
MeSH: D008269
OMIM: 153880
Reference
  Authors
Rotsos TG, Moschos MM
  Title
Cystoid macular edema.
  Journal
Clin Ophthalmol 2:919-30 (2008)
Reference
  Authors
Romero-Aroca P
  Title
Managing diabetic macular edema: The leading cause of diabetes blindness.
  Journal
World J Diabetes 2:98-104 (2011)
DOI:10.4239/wjd.v2.i6.98
Reference
  Authors
Fardeau C, Champion E, Massamba N, LeHoang P
  Title
Uveitic macular edema.
  Journal
Eye (Lond) 30:1277-1292 (2016)
DOI:10.1038/eye.2016.115
Reference
PMID:27330464 (drug)
  Authors
Andreoli MT, Pinnolis M, Kieser T, Sun J, Andreoli CM
  Title
Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration.
  Journal
Digit J Ophthalmol 21:1-17 (2015)
DOI:10.5693/djo.01.2015.04.002
LinkDB All DBs

» Japanese version

DBGET integrated database retrieval system